Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

UV Innovators™ Releases the First UV Handheld Proven to Inactivate COVID Virus in 2 Seconds


The results from the rigorous study completed at Texas Biomedical Research Institute demonstrated that NuvaWave killed >99.9% of the live virus in just two seconds.

UV Innovators (http://www.uvinnovators.com), an ultraviolet technology company, today launched NuvaWave, one of the most advanced tools in the fight against deadly pathogens. NuvaWave is a UVC handheld device that is used to disinfect any high touch surface. This product release is timely as all businesses, schools, municipalities, airlines, cruise ships and other commercial ventures need to have a solution to protect their employees, students, customers and family from COVID.

“In order for people to feel comfortable getting back to normal, they must feel confident that the places they go are clean and free from infectious pathogens. NuvaWave is a commercial-grade solution for those who are disinfecting high-touch surfaces,” stated Dr. Nicholas Medendorp, Jr., a technology leader with over two decades of LED experience and 115 patents and CEO of UV Innovators. “NuvaWave has undergone rigorous testing with accredited third-party laboratories to gauge its efficacy in killing SARS-CoV-2, the virus that causes COVID-19. The results from the rigorous study completed at Texas Biomedical Research Institute demonstrated that NuvaWave killed >99.9% of the live virus in just two seconds,” added Dr. Medendorp.

NuvaWave was tested at Texas Biomed, (via a sponsored study by UV Innovators), an independent, nonprofit research institute whose mission is to protect our global community from the threats of infectious diseases through cutting-edge research. “For nearly three quarters of a century, the Institute has delivered high quality and reliable scientific data, spanning basic discovery through preclinical development,” explained Dr. Cory Hallam, Professor and Vice President for Business Development at Texas Biomed. “The scientists at Texas Biomed know how to handle the live virus in their biosafety level 3 (BSL-3) lab and to use protocols to safely mimic real-world conditions that helped us document the effectiveness of NuvaWave,” added Dr. Medendorp.

NuvaWave handheld device only weighs 1.5 pounds and provides 5,000 hours of disinfection. UV Innovators’ break-through technology changes the paradigm in making hospital-grade technology affordable. UV Innovators is announcing the NuvaWave Fleet Program that enables infection control teams a simple and affordable monthly payment. To place an order, visit http://www.uvinnovators.com today.

The report from Texas Biomed can be found here.

About UV Innovators

UV Innovators, LLC uses its extensive illumination and medical device knowledge to create intellectual property that delivers disinfection solutions across a vast set of markets — from private aviation and clinical care facilities, to healthy office buildings and schools. The commercialization of a UVC product that delivers the germ deactivating power of a disinfection tower, with the speed and mobility of a handheld device, UV Innovators has redefined the standard of surface disinfection. For more information, visit http://www.uvinnovators.com or contact info@uvinnovators.com.

Share article on social media or email:

Interbit Data Announces Webinar for Hospital Leaders


News Image

Our mission at Interbit Data is to make healthcare data accessible anytime, anywhere, to empower frontline care workers to deliver safe, high-quality care,” says Arthur Young, President and CEO of Interbit Data.

Interbit Data, a leading technology company providing care teams with on-demand access to crucial patient data, will host a webinar on Tuesday, October 20, to share how virtual fax over IP (FoIP) options are revolutionizing the way hospitals and health systems deliver care.

The webinar, “Deliver Healthcare Anywhere with Fax over IP,” will highlight a case study from one hospital in rural Wyoming that uses Interbit Data’s NetFoIP solution (a NetDelivery module) to enable its orthopedic specialists to deliver care to a wider geographic area. Because of NetFoIP, the hospital is able to send orthopedic specialists up to 200 miles away, where they can rent temporary office space, which prevents patients from needing to travel several hours to the hospital for post-surgical follow ups and eliminates the need for a full office setup including costly and cumbersome equipment such as physical printers and fax machines.

“Our mission at Interbit Data is to make healthcare data accessible anytime, anywhere, to empower frontline care workers to deliver safe, high-quality care,” says Arthur Young, President and CEO of Interbit Data. “This case study is a perfect example of that mission, illustrating how NetfoIP enables this rural health system to keep their doors open and helps to extend specialist care to communities who otherwise would lack access. Our products help both patients and businesses and push the boundaries and limitations of healthcare.”

Interbit Data’s NetDelivery is a HIPAA-compliant report distribution solution that delivers information from hospital healthcare information systems to clinicians and staff, helping hospitals to improve efficiencies, streamline workflows and provide optimal patient service and high-quality care. NetFoIP, a NetDelivery module, provides completely virtualized faxing, enabling hospitals to improve operational efficiency, remove hardware constraints, and create automatic fail-over configurations. NetFoIP provides software-enabled fax over IP (FoIP) without requiring an existing voice over IP (VoIP) network or phone system. NetFoIP allows hospitals to:


  • Transmit IP-enabled faxes even without Voice over IP (VoIP)
  • Remove or consolidate fax machines and modems, reducing equipment and maintenance costs and eliminating hardware failures
  • Manage all incoming faxes in Microsoft Windows directories using NetFoIP’s optional Inbound Fax Client

Hospitals and health system leaders, healthcare IT vendors, industry consultants and members of the media are invited to attend the upcoming webinar:

Webinar: Deliver Healthcare Anywhere with Fax over IP

Date: Tuesday, October 20, 2020

Time: 1:00 – 1:45 pm ET

Click To Register

About Interbit Data

Interbit Data is an industry leader in data accessibility for hospitals and health systems. Our software solutions ensure secure, reliable access to patient information anytime, anywhere – including at offsite locations, during system downtimes, and even during cyberattacks. With 23+ years in business and more than 700 customers across North America, we are experts at data access and report distribution, empowering you to improve efficiency, streamline workflows, provide optimal patient service and high-quality care, all while meeting federal patient privacy and access requirements. Discover more at interbitdata.com.

Share article on social media or email:

HaHa Cannabis Beverages Launch across Nevada and at Planet 13 Las Vegas


HaHa Hint of Berry

Like our popular HaHa gummies, which have the slogan ‘a burst of laughter in every bite’ our HaHa Cannabis Beverages are made for good vibes only

Planet 13, a leading vertically-integrated Nevada cannabis company, has launched HaHa Cannabis Beverages, now on shelves at the SuperStore, and soon to be available in over 35 dispensaries across the state.

HaHa sparkling flavored beverages are available in five flavors: Orange, Lime, Lemon, Berry, and Grapefruit. All flavors are zero calorie, zero sugar using all-natural fruit flavorings and designed for an uplifting high. HaHa recipes celebrate the free, fun-loving spirit of cannabis enthusiasts and are created with love by passionate, enthusiastic chefs. HaHa’s high-quality products are infused with people’s favorite tasty varieties of flavors.

“Like our popular HaHa gummies, which have the slogan ‘a burst of laughter in every bite’ our HaHa Cannabis Beverages are made for good vibes only,” said Larry Scheffler, Co-CEO of Planet 13. “Our HaHa products are the first cannabis beverages to be launched with this variety of chef inspired flavors.”

HaHa beverages are now part the Planet 13 brand success story. Planet 13 brands continue to perform well at the SuperStore, up from 14% in Q4, 2019 to 28.5% of sales in Q2, 2020 (reported on August 31, 2020).

“Our owned brands, with their focus on quality and natural ingredients, are a big hit with consumers,” said Bob Groesbeck, Co-CEO of Planet 13. “Our products are also available in dispensaries across Nevada, and we have multiple SKUs in the top 10 of their respective categories; edibles, concentrates, and beverages*.”

The Planet 13 SuperStore is located at 2548 W. Desert Inn Rd., Las Vegas – just off The Strip. For more information and SuperStore hours visit Planet13LasVegas.com.

*https://www.headset.io/

About Planet 13

Planet 13 (http://www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas – the entertainment capital of the world. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s common shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and on the OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through its subsidiary MMDC. Local state laws where MMDC operates permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated April 30, 2019 filed on its issuer profile on SEDAR at http://www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Share article on social media or email:

Current and Future Strategies, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Efficiently managing this level of complexity and avoiding delays in reaching database lock requires a strategic approach that can track, QC, reconcile and ensure the veracity of a rapid inflow of non-CRF data.

As clinical trials are incorporating an increasing number of sources of non-case-report-form (CRF) data from wearable devices and various laboratories, management of clinical data must address larger, disparate volumes of external data sources. These non-CRF clinical data can cause delays in resolving queries and can place additional burden on eCRF data managers.

Efficiently managing this level of complexity and avoiding delays in reaching database lock requires a strategic approach that can track, QC, reconcile and ensure the veracity of a rapid inflow of non-CRF data.

In this webinar, our thought leaders discuss best practices for dealing with these complex data structures and implementing a data strategy that not only addresses needs for today, but also explores future tactics for proactively optimizing management of external data sources.

Join Arshad Mohammed, MBBS, Global Head CDM, Covance FSPx and David Howard, BSC(Hons), Global Head of External and Clinical Data Strategy, Covance FSPx, for the live webinar on Tuesday, September 29, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Managing External Data Sources in Clinical Trials: Current and Future Strategies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

From Atherosclerosis to COVID-19, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

The biology of adipose tissue inflammation also offers unique insights into a variety of diseases, ranging from diabetes to COVID-19.

Vascular inflammation is a critical factor in both atherosclerotic plaque formation and subsequent plaque rupture. The role of inflammation in atherosclerosis has recently gained further prominence with clinical trials such as CANTOS and COLCOT, showing that reducing systemic inflammation improves clinical outcome. There is now an increased focus on targeting residual coronary inflammatory risk as a viable therapeutic target in cardiovascular drug development.

Currently, available tests for the detection of coronary artery inflammation are either non-specific for the cardiovascular system (e.g., plasma biomarkers) or expensive and not readily available (e.g., hybrid positron emission tomography imaging). Novel methods for the non-invasive quantification of coronary inflammation, through analysis of changes in perivascular adipose tissue attenuation (or radiodensity) in coronary computed tomography angiography, allow us to overcome many of the limitations of existing biomarkers and could be a valuable tool for the quantification of residual inflammatory risk, cardiovascular risk stratification and evaluating the treatment effect of novel anti-inflammatory therapies.

The biology of adipose tissue inflammation also offers unique insights into a variety of diseases, ranging from diabetes to COVID-19.

This field of scientific research has been pioneered by Professor Charalambos Antoniades, who is a Deputy Head of the Division of Cardiovascular Medicine at the University of Oxford and Chairman-Elect of the British Atherosclerosis Society. He will provide an overview of the field and its applicability to enable the design of precision cardiovascular trials.

Join Dr. Charalambos Antoniades along with Dr. Cheerag Shirodaria, Vice President Cardiovascular Medicine, Covance, Honorary Consultant Cardiologist, Oxford University Hospitals NHS Foundation Trust for the live webinar on Monday, September 28, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Perivascular Fat Inflammation: From Atherosclerosis to COVID-19.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Comagine Health, Mathematica and Allegis Partner on Washington State Contact Tracing Contract


Marc Bennett, Comagine Health’s president and chief executive officer said. “Contract tracing is a key part of this strategy and we’re proud to be able to offer our long-standing community relationships to support our partners in the effort to contain the virus.”

Comagine Health, a leading national nonprofit health care consulting firm, is partnering with Mathematica and Allegis to support the Washington State Department of Health to reduce the spread of the novel coronavirus. The Washington COVID-19 Contact Tracing Partnership will supplement a comprehensive contact tracing program by bolstering community-based response and enabling rapid and effective analysis of data collected through the effort.

“The coronavirus pandemic has illuminated the need for a comprehensive strategy to reduce its spread,” Marc Bennett, Comagine Health’s president and chief executive officer said. “Contact tracing is a key part of this strategy and we’re proud to be able to offer our long-standing community relationships to support our partners in the effort to contain the virus.”

As a part of this effort, Comagine Health is actively establishing a Community Partnership Council (CPC) to bring together key community stakeholders to inform and strengthen the contact tracing effort and ensure local needs are met in each community. The CPC will advise on key challenges facing vulnerable communities and will collaboratively surface opportunities to help improve the impact of the contract tracing program.

Dan Lessler, Comagine Health’s chief clinical officer added, “We look forward to bringing our trusted relationships with communities across Washington state together to support our partners in this important effort to contain the pandemic.”

“Our vision is to serve the state of Washington as a trusted partner and ideal collaborator,” said Candace Miller, Mathematica’s project director. “We’re ready to immediately mobilize and help reduce the spread of COVID-19.”

In addition to supporting communities with contact tracing, Comagine Health is also helping health care organizations respond to the pandemic using:

Advanced Analytics — Through provider centered analytics, academic research and public content, Comagine Health’s advanced analytics help health care professionals see the broader impact of the COVID-19 pandemic and plan for the long-term.

Infection Prevention and Control — Comagine Health offers education and consultation for infection prevention and control to help protect staff and patients, create a standardized, evidence-based approach to infection prevention and mitigate costs associated with the COVID-19 pandemic.

Telehealth and Virtual Services — Comagine Health’s training and consultation for telehealth and virtual services expand health care service delivery options, enhance access for vulnerable populations, and improve care outcomes and other clinical quality measures.

About Comagine Health

Comagine Health, formerly Qualis Health and HealthInsight, works collaboratively with patients, providers, payers and other stakeholders to reimagine, redesign and implement sustainable improvements in the health care system. As a trusted, neutral party, we work in our communities to address key, complex health and health care delivery problems. In all our engagements and initiatives, we draw upon our expertise in quality improvement, care management, health information technology, analytics and research. We invite our partners and communities to work with us to improve health and redesign the health care delivery system. For more information, please visit comagine.org.

Share article on social media or email:

A Preview of Bio-IT World Conference & Expo 2020


Bio-IT World Conference & Expo Virtual

Bio-IT World Conference & Expo Virtual
October 6-8, 2020

And for the first time ever, many presentations will be available on demand after their first showing. Attendees will be able to learn more, ask more questions, and derive more value from the program for weeks and months to come.

Bio-IT World Conference & Expo Virtual kicks off on October 6th, 2020. The program this year includes three days full of content, networking, and interaction across 16 tracks, plenary session, workshops, posters, awards, and happy hours. The virtual meeting platform offers integrated tools to stay connected with colleagues, reach out to speakers, ask questions during presentations and live Q&A panels, and tour virtual exhibit booths.

And for the first time ever, many presentations will be available on demand after their first showing. Attendees will be able to learn more, ask more questions, and derive more value from the program for weeks and months to come.

We are already busy marking our agendas—notations we’ll be able to transfer to the virtual platform soon. Here’s some of what is our on current list.—The Editors

As usual, the event kicks off with workshops designed to be instructional, interactive and in-depth. This year topics include data management for biologics, a crash course in AI, data science-informed decisions, data at scale, and more.

The 2020 Bio-IT World plenary program is exceptional. Susan Gregurick, NIH’s Office of Data Science Strategy, and Rebecca Baker, Director, HEAL, will share NIH’s strategic vision for data science, and how the the pandemic will shape NIH’s future. Tuesday, October 6

Robert Green, Brigham & Women’s Hospital and Harvard Medical School will share fascinating news on his latest sequencing project. And Natalija Jovanovic, Sanofi Pasteur, will share pharma’s view of the AI-enabled future. Thursday, October 8

A panel of experts including Seth Cooper, Northeastern University; Lee Lancashire, Cohen Veterans Bioscience; Pietro Michelucci, Human Computation Institute; and Jérôme Waldispühl, McGill University will tackle how AI, citizen science, and human computation are working together with the help of gaming. Wednesday, October 7

Rare disease patients suffer too often from long diagnostic delays and misidentified diseases. This creates a significant burden, not just for patients, but for healthcare systems. Tom Defay, Alexion, will share examples of collaboration with researchers and hospital systems to develop novel approaches for rare disease patient identification using tools like genomics, machine learning, and NLP. Thursday, October 8

Biomedical research over the last decade has become increasingly complex, and different disciplinary experts are needed to solve challenging scientific questions. No longer is a single disciplinary perspective enough for truly breakthrough research advances. L. Michelle Bennett, NIH NCI, explores how to build the most impactful interdisciplinary teams and how to keep them working effectively. (For more, see our conversation with Michelle at Training Scientists For Our Interdisciplinary Future.) Wednesday, October 7

John Quackenbush, Harvard Medical School, will outline how his group uses networks to understand genetic and genomic drivers of disease. By using innovative computational methods built around network representations of biological interactions, we can gain insight into the disease process, develop predictive biomarkers, and identify possible avenues of therapeutic intervention, he argues. Wednesday, October 7

Alexander Sherman, Massachusetts General Hospital, will describe how MGH is pursuing patient centricity to bring such information together and bridge clinical trials data with RWD, such as data from EHRs, DNA sequences, image banks, biobanks, -omics, etc. We are introducing patient-centric approaches with a unique secure patient identification and aligning incentives for all players in a research continuum, including academia, industry, government, patient advocates, and patients. Wednesday, October 7

Matthew Trunnell, Data Commoner-at-Large (former Vice President and Chief Data Officer, Fred Hutchinson Cancer Research Center) will present the Cascadia Data Discovery Initiative, and its goal to accelerate health innovation and cancer research through collaboration, data sharing, and data-driven research. Wednesday, October 7

Many critical facts required by healthcare AI applications are locked in unstructured free-text data. Recent advances in deep learning have raised the bar on achievable accuracy for tasks, like named entity recognition, entity resolution, de-identification and others, using novel healthcare-specific networks and models. Vishakha Sharma, Roche Molecular Systems, will discuss how Roche applies the greatest advances in AI for healthcare to extract clinical facts from pathology reports and radiology. She will then detail the design of the deep learning pipelines used to simplify training, optimization, and inference of such domain-specific models at scale. Wednesday, October 7

Digital transformation is still a driving principle in pharma R&D with the ultimate goal being to streamline processes and enable precision medicine. Anastasia Christianson, Janssen Pharmaceuticals, will present examples of digital technologies driving transformation and tangible results in R&D. Wednesday, October 7

In a pair of talks from Bristol-Myers Squibb speakers, Ajay Shah and Albert Wang will present Sage, a comprehensive platform for innovation with data and how BMS researchers use Sage to maximize real-world assets. Shah will start by giving an overview of essential components of the platform, such as uniform high-quality data ingestion, data lake enhancement with semantic integration conformance of data, and a reproducible research framework. Wang will highlight how Sage catalogs, models, integrates, conforms, and presents patient-level metadata across all RWD assets to facilitate downstream cross-dataset analysis within an integrated managed analytics environment. This talk will touch on the business drivers for this initiative, our current progress, as well as some lessons learned. Wednesday, October 7

Read the Full Preview

View the Conference Agenda

NeuroFlow Adds to Executive Leadership Team with New VP of Sales


NeuroFlow, the leading provider of digitally integrated behavioral health solutions, has hired Neal Smart as the Vice President of Sales. This completes the company’s organizational C-Suite at a time when financials indicate a significant ‘7X’ year-over-year growth multiple.

Smart, a management executive arriving from Zocdoc, a leading patient appointment booking platform, was promoted several times during his six-year tenure and recognized on the company’s annual ‘President’s Club’ list for sales excellence. Prior to this experience, Smart served as an executive client director for GE Healthcare, ushering in new technology innovations in remote patient monitoring, medical diagnostics, and other IT advancements. He joins Vice President of Marketing James Coates and Vice President of Engineering Jeff Burk as new additions to the seasoned executive team.

“Neal understands the unmet demand for technology in today’s healthcare landscape and sees an opportunity for health systems to bridge the gap between physical and behavioral health offerings,” said NeuroFlow Head of Growth and Chief Operating Officer Adam Pardes. “We’ve now assembled the pieces — through recruitment and developing talent internally — to get our product and services to the next level.”

NeuroFlow, which now counts 50 employees and thousands of health providers as customers, has used 2020 to enhance its platform’s capabilities for delivering tailored, real-time mental health care. Since the onset of the COVID-19 pandemic, the company has experienced a period of high usage and sales demand, creating larger contract opportunities in the healthcare industry.

“It’s an exciting time to join a leader in the field of behavioral health,” said Smart. “We know that despite the tremendous demand for technology in healthcare settings, there’s still an education curve that we need to flatten in the industry. With the experience and expertise of my colleagues, I am not only honored to join them but am extremely confident that NeuroFlow will continue to be an innovator with ambitious goals for improving the mental health of large populations.”

In recent months, NeuroFlow has rolled out its platform with independent medical groups, leading health plans, federal government organizations, and major health system networks. The company’s growth was measured by analyzing the annual recurring revenue of contracts.

About NeuroFlow

NeuroFlow is a digital health company combining workflow automation, consumer engagement solutions, and applied AI to promote behavioral health integration in all care settings. NeuroFlow’s suite of HIPAA-compliant, cloud-based tools simplify remote patient monitoring, enable risk stratification, and facilitate collaborative care. With NeuroFlow, health care organizations can finally bridge the gap between mental and physical health in order to improve outcomes and reduce the cost of care. http://www.neuroflow.com.

Share article on social media or email:

Gauss and Cellex partner on first at-home COVID-19 rapid antigen test and computer vision mobile app


News Image

Gauss, the leading developer of computer vision applications for healthcare, and Cellex, a leading biotechnology company specializing in point-of-care diagnostic testing, today announced an exclusive partnership to launch the first-ever rapid, at-home and point-of-care COVID-19 antigen test. If authorized by the Food and Drug Administration (FDA) under Emergency Use Authorization (EUA) this fall, the test would be the first allowing people to test themselves for active COVID-19 infection and receive rapid results within the confines of their own home or similar user environments.

Cellex, which was the first company to receive an FDA Emergency Use Authorization for rapid COVID-19 antibody testing on April 1, 2020, is now in advanced clinical trials with a rapid antigen test that targets the nucleocapsid (N) protein on the SARS-CoV-2 virus and has demonstrated nearly 90% sensitivity and 100% specificity in early trials. When paired with a newly developed, AI-powered application from Gauss that enables non-expert users to perform and interpret the test with an iPhone or Android phone, its use can be expanded to aid in the rapid diagnosis of SARS-CoV-2 infections in both at-home and point-of-care settings.

To perform at-home testing, users follow step-by-step video instructions in the app to correctly collect a nasal swab sample and perform the rapid antigen test. Within 15 minutes, the app prompts the user to scan their rapid test with their smartphone and then processes the image with an end-to-end neural network architecture optimized for the Cellex assay. The app informs the user if the test result is negative or positive for SARS-CoV-2 antigens within seconds. Gauss’s patent-pending, AI-driven assay reading technology overcomes the limit of detection of the untrained human eye and can also minimize inter-reader variability routinely seen in interpreting antigen test results. Put together, the solution will deliver fast and reliable results on an encrypted, HIPAA-compliant, consumer-friendly app.

The Gauss-Cellex announcement comes amidst a growing consensus among public health officials and business leaders that a widely-accessible rapid antigen testing solution is needed to decrease the public health threat from COVID-19 and mitigate the pandemic’s economic impact until a vaccine is widely available. A rapid, reliable, inexpensive and consumer-friendly at-home antigen test would significantly reduce virus transmission, particularly by asymptomatic and pre-symptomatic patients, while enabling people with negative results to engage in their day-to-day activities – from going to work, going to school, shopping, visiting a relative or vacationing – with a significantly lower risk of transmission. However, widespread use of rapid tests is currently limited by the need for trained clinical operators or specialized laboratory equipment to ensure that tests are performed and interpreted accurately.

“The integration of Cellex’s accurate, at-home rapid antigen test with Gauss’s mobile app offers a scalable solution to significantly reduce transmission of COVID-19 and help society mitigate the impacts of the pandemic until a vaccine is widely available,” Gauss Founder and CEO Siddarth Satish said. “By embedding advanced computer vision algorithms within a thoughtfully-designed user experience, we can enable consumers to perform a rapid test in their own homes just as well as a trained operator or a laboratory instrument – simply by using their smartphone cameras.”

“The partnership between Gauss and Cellex is highly synergistic and natural,” Cellex Founder and CEO James Li, PhD said. “While Gauss has deep expertise in applied computer vision and FDA-cleared mobile apps, Cellex has been pioneering technologies for point of care diagnosis, including rapid testing for SARS-CoV-2. This AI-enabled COVID-19 antigen test for home use will make self-monitoring and isolation feasible, thereby playing a significant role in changing the trajectory of the COVID-19 pandemic in America and beyond.”

In addition to reading tests and displaying results, the Gauss app can facilitate automatic reporting of data to health authorities and give users a mobile pass temporarily storing their status. For point-of-care and laboratory users, the app can enable clinical users to automatically send data to electronic medical record (EMR) and laboratory information systems as well. The Gauss app is available on the Apple App Store and is already being used by research teams at two prominent universities to power large-scale, at-home research studies on COVID-19.

Learn more about the Gauss-Cellex rapid antigen test at http://covid19.gauss.com.

About Gauss: Gauss is the leader in computer vision in healthcare. Founded in 2011, Gauss’s mission is to digitally augment clinicians with software that radically improves diagnostic accuracy and leads to improved patient safety and clinical outcomes. Gauss’s flagship product, Triton, leverages computer vision to detect surgical and obstetric hemorrhage in real time and notifies clinicians who can enact timely intervention and treatment. Triton was granted De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014, as the first-ever computer vision software for surgical use, and several follow-on 510(k) clearances. Available on the iPhone, Triton has been widely adopted by health systems in the United States and is a recipient of the Apple Design Award, which recognizes the best in design, innovation and technology on Apple platforms. For more information, visit http://www.gauss.com.

About Cellex: Founded in 2002, Cellex is a pioneer accelerating the era of decentralized medicine. Cellex’s suite of diagnostics products for combating infectious diseases is based upon innovative point-of-care (POC) platform technologies. On April 1, 2020, Cellex was the first company to receive an FDA Emergency Use Authorization for a COVID-19 antibody test. Its rapid tests have been in widespread use by several states in the U.S.A and across the globe through the COVID-19 pandemic. To learn more, visit http://www.cellex.us.

Share article on social media or email:

Sachi & Co. Dentistry Announces New Hybrid-Responsive Website


Sachi & Co. Dentistry of Torrance, CA

Sachi & Co. Dentistry of Torrance, CA

We use the latest technology as another tool to improve and simplify the way your care team communicates with you. We hope you find our new website helpful in your daily lives.

Sachi & Co. Dentistry of Torrance, CA is pleased to announce the launch of their new Hybrid-Responsive™ website: https://www.sachidentistry.com.

The team at Sachi & Co. embraces patient education as one of their dental practice’s core missions and through their Hybrid-Responsive website, they’re able to reach patients in an entirely new way. Built with usability at the forefront, the new website offers patients a seamless online experience with a clean, uncluttered design. It’s easier than ever for patients to learn more about potential treatments, financing, and post-operative instructions.

“We feel clear and convenient communication is an essential element of caring for you, our patients. We use the latest technology as another tool to improve and simplify the way your care team communicates with you. For instance, immediate access to information like post-operative instructions and emergency questions helps you stay on pace with busy lives, and accessibility to information helps loved ones to be involved in making decisions. We hope you find our new website helpful in your daily lives,” says Dr. Sachi Fujita.

The new Sachi & Co. website is equally responsive on laptops, desktop computers, tablets, and smartphones, allowing patients to easily access the information they need whether they’re at work, at home, or on-the-go. With a few simple clicks or taps on the screen, users can interact with the practice, fill out new patient forms, schedule appointments online, and more.

About Dr. Sachi Fujita

Dr. Fujita graduated from dental school at the University of California in San Francisco before founding her dental practice. Through dentistry, she is able to combine her passion for improving the lives of others with her artistic abilities, creating smiles that are as healthy as they are beautiful. She specializes in cosmetics, restoring complex cases and implant dentistry.

About Dr. Sho Izumi

Dr. Izumi attended dental school at Loma Linda University and is a member of the American Dental Association, the California Dental Association, and Harbor Dental Society. Her interest in dentistry started when she received orthodontic treatment as a child; now, Dr. Izumi is able to help her patients achieve the smiles they’ve always wanted.

About Dr. Tiffany Chin

After earning her dental degree from the University of Medicine and Dentistry of New Jersey, Dr. Chin completed a General Practice Residency at the Nassau University Medical Center in Long Island, NY. She joined the team at Sachi & Co. Dentistry shortly after relocating to the West Coast, where she enjoys putting her eye for detail and artistic talents to use for her patients.

About Dr. Peter Cacos

A native of British Columbia, Dr. Cacos earned his dental degree from the University of Southern California School of Dentistry. He specializes in cosmetic and general dentistry services and prides himself on treating each patient like a member of his family.

About Sachi & Co. Dentistry

Sachi & Co. Dentistry provides a full range of dental services in a modern, comfortable environment. Treatments and procedures include dental implants, restorative dentistry, Invisalign, periodontal care, and more. To learn more or request an appointment, visit the new website at https://www.sachidentistry.com or call (310) 530-9893. Sachi & Co. Dentistry is located at 3440 Lomita Blvd., Suite 340, Torrance, CA 90505.

Share article on social media or email: